Objective: The aim of this study was to compare the clinical emcacy of integration of traditional Chinese medicine (TCM) and we stern medicine, and the western medicine therapy for H type hypertension. Methods: The ra...Objective: The aim of this study was to compare the clinical emcacy of integration of traditional Chinese medicine (TCM) and we stern medicine, and the western medicine therapy for H type hypertension. Methods: The randomized contmlled trials were collected via searching the internet. The literatures were screened according to inclusion and exclusion criteria. All the assignments were performed by two researchers. If there was disagreement between the two researchers, we would ask evidence based medicine expert for advice, to get an optimal result. The database included the ChianInfo (1978—2015), the Superstar database (1955—2017), the CBM(1985—2017), CNKI(1984—2017), PubMed(1966—2017). Accordingto Meta analysis, the RevMan 5.2 software was used to recover and analyze the literatures, and make the assessment of the integration of TCM and westem medicine in treating H Type Hypertension. Results: In the study, 12 trials were included. The total number of cases is 1139. The Meta analysis results showed that: Compared with western medicine the integration of TCM and western medicine would improve the antihypertensive efficacy [OR=0.39, 95%CI (0.25, 0.59), Z=4.38(P< 0.0001)],lower Hcy levels [WMD=-1.93, 95%CI (-2.27, 0.21), Z=4.38 (P< 0.0001)]. Conclusion: The combination therapy can effectively reduce Hcy levels, control blood pressure, better than Western medicine.展开更多
A multifunctional integrated microfluidic biochip device was engineered to estimate the activity-toxicity and composition principle of medicine in a cell model in vitro. This biochip could be used for disease cells an...A multifunctional integrated microfluidic biochip device was engineered to estimate the activity-toxicity and composition principle of medicine in a cell model in vitro. This biochip could be used for disease cells and healthy cells in two modules of "Yin-Yang" on the same chip for detecting the medicine efficacytoxicity simultaneously, as well as adjust different gradient ratios of concentration through the Christmas tree structure in both "Yin-Yang" modules autonomously for detecting the best compatibility of medicine in maximum efficacy and minimal toxicity. In the applicability experiment, the best concentration of three chemical compounds including dinatin, diosmetin and cisplatin, were detected using the biochip and traditional 96-cell plate. Biochip assays showed perfect positive correlation compared with the results of traditional 96-cell plate, in addition presented advantages as less detection time and much lower price than the traditional 96-cell plate, which indicated the biochip is both convenient and feasible.Thus, the novel microfluidic chip-based multifunctional integrated system congregated the virtues of high throughput, rapid, sensitive, specific, cost-effective, and similar to the physical environment of the human body, which was especially suitable for the medicine efficacy-toxicity and compatibility evaluation.展开更多
目的:系统评价中西医结合治疗癌痛的临床疗效及安全性。方法:电子检索1990年1月—2014年10月7个中外文数据库,两名研究者据纳排标准交叉核对,纳入中西医结合治疗癌痛的随机对照临床试验(randomized controlled trail,RCT),提取纳入文献...目的:系统评价中西医结合治疗癌痛的临床疗效及安全性。方法:电子检索1990年1月—2014年10月7个中外文数据库,两名研究者据纳排标准交叉核对,纳入中西医结合治疗癌痛的随机对照临床试验(randomized controlled trail,RCT),提取纳入文献有效信息。按照Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0对纳入RCT进行偏倚风险评估,采用统计软件Rev Man 5.3.4进行Meta分析。结果:共纳入67篇RCTs,Meta分析结果显示:与单纯西医治疗比较,中西医结合治疗癌痛可以提高镇痛疗效[NRS法:RR=1.34,95%CI(1.28,1.39),P<0.0001;VAS法:RR=1.19,95%CI(1.09,1.30),P<0.0001;PAR法:RR=1.15,95%CI(1.05,1.25),P=0.002],改善癌痛患者生存质量[RR=1.30,95%CI(1.22,1.59),P<0.0001],减少不良反应发生[恶心呕吐:RR=0.50,95%CI(0.44,0.57),P<0.00001;头昏嗜睡:RR=0.54,95%CI(0.42,0.70),P<0.00001;便秘:R=0.25,95%CI(0.18,0.34),P<0.00001]。结论:与单纯西医组比较,中西医结合治疗组在提高镇痛疗效、改善癌痛患者生存质量和降低镇痛药物不良反应方面有统计学差异,但由于纳入文献50%以上存在高度偏倚风险,且安全性评价存在发表偏倚,文献质量偏低,尚需大量多中心、大样本的随机对照临床试验验证其临床效果。展开更多
目的观察不可手术的中心型非小细胞肺癌患者应用全程局部同步推量适形放射治疗的不良反应及临床疗效。方法收集2007年12月至2013年7月在河北医科大学第四医院收治的不可手术的中心型非小细胞肺癌患者44例,均经组织学或细胞学证实,采用SI...目的观察不可手术的中心型非小细胞肺癌患者应用全程局部同步推量适形放射治疗的不良反应及临床疗效。方法收集2007年12月至2013年7月在河北医科大学第四医院收治的不可手术的中心型非小细胞肺癌患者44例,均经组织学或细胞学证实,采用SIB-CR技术制定放疗计划,PTV处方剂量5 040 c Gy/28次(180 c Gy/次),肿瘤局部处方剂量6 440 c Gy/28次(单次分割230 c Gy/次),1次/日,5次/周,全程放疗时间5.5周。观察不良反应及临床疗效。结果放疗结束疗效显示:总有效率为97.70%(43/44)。全组病例1、2、3、5年生存率分别为70.9%、44.8%、31.0%、18.6%。1、2、3、5年局部控制率分别为93.8%、63.9%、58.1%、58.1%。急性放射性肺炎和放射性食管炎的发生率分别为29.6%和25%。骨髓抑制发生率为43.2%(19/44)。结论全程局部同步推量适形放射治疗不可手术的中心型非小细胞肺癌,临床有效率高,患者耐受性好。长期生存和晚期并发症有待于进一步观察。展开更多
文摘Objective: The aim of this study was to compare the clinical emcacy of integration of traditional Chinese medicine (TCM) and we stern medicine, and the western medicine therapy for H type hypertension. Methods: The randomized contmlled trials were collected via searching the internet. The literatures were screened according to inclusion and exclusion criteria. All the assignments were performed by two researchers. If there was disagreement between the two researchers, we would ask evidence based medicine expert for advice, to get an optimal result. The database included the ChianInfo (1978—2015), the Superstar database (1955—2017), the CBM(1985—2017), CNKI(1984—2017), PubMed(1966—2017). Accordingto Meta analysis, the RevMan 5.2 software was used to recover and analyze the literatures, and make the assessment of the integration of TCM and westem medicine in treating H Type Hypertension. Results: In the study, 12 trials were included. The total number of cases is 1139. The Meta analysis results showed that: Compared with western medicine the integration of TCM and western medicine would improve the antihypertensive efficacy [OR=0.39, 95%CI (0.25, 0.59), Z=4.38(P< 0.0001)],lower Hcy levels [WMD=-1.93, 95%CI (-2.27, 0.21), Z=4.38 (P< 0.0001)]. Conclusion: The combination therapy can effectively reduce Hcy levels, control blood pressure, better than Western medicine.
文摘A multifunctional integrated microfluidic biochip device was engineered to estimate the activity-toxicity and composition principle of medicine in a cell model in vitro. This biochip could be used for disease cells and healthy cells in two modules of "Yin-Yang" on the same chip for detecting the medicine efficacytoxicity simultaneously, as well as adjust different gradient ratios of concentration through the Christmas tree structure in both "Yin-Yang" modules autonomously for detecting the best compatibility of medicine in maximum efficacy and minimal toxicity. In the applicability experiment, the best concentration of three chemical compounds including dinatin, diosmetin and cisplatin, were detected using the biochip and traditional 96-cell plate. Biochip assays showed perfect positive correlation compared with the results of traditional 96-cell plate, in addition presented advantages as less detection time and much lower price than the traditional 96-cell plate, which indicated the biochip is both convenient and feasible.Thus, the novel microfluidic chip-based multifunctional integrated system congregated the virtues of high throughput, rapid, sensitive, specific, cost-effective, and similar to the physical environment of the human body, which was especially suitable for the medicine efficacy-toxicity and compatibility evaluation.
文摘目的:系统评价中西医结合治疗癌痛的临床疗效及安全性。方法:电子检索1990年1月—2014年10月7个中外文数据库,两名研究者据纳排标准交叉核对,纳入中西医结合治疗癌痛的随机对照临床试验(randomized controlled trail,RCT),提取纳入文献有效信息。按照Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0对纳入RCT进行偏倚风险评估,采用统计软件Rev Man 5.3.4进行Meta分析。结果:共纳入67篇RCTs,Meta分析结果显示:与单纯西医治疗比较,中西医结合治疗癌痛可以提高镇痛疗效[NRS法:RR=1.34,95%CI(1.28,1.39),P<0.0001;VAS法:RR=1.19,95%CI(1.09,1.30),P<0.0001;PAR法:RR=1.15,95%CI(1.05,1.25),P=0.002],改善癌痛患者生存质量[RR=1.30,95%CI(1.22,1.59),P<0.0001],减少不良反应发生[恶心呕吐:RR=0.50,95%CI(0.44,0.57),P<0.00001;头昏嗜睡:RR=0.54,95%CI(0.42,0.70),P<0.00001;便秘:R=0.25,95%CI(0.18,0.34),P<0.00001]。结论:与单纯西医组比较,中西医结合治疗组在提高镇痛疗效、改善癌痛患者生存质量和降低镇痛药物不良反应方面有统计学差异,但由于纳入文献50%以上存在高度偏倚风险,且安全性评价存在发表偏倚,文献质量偏低,尚需大量多中心、大样本的随机对照临床试验验证其临床效果。
文摘目的观察不可手术的中心型非小细胞肺癌患者应用全程局部同步推量适形放射治疗的不良反应及临床疗效。方法收集2007年12月至2013年7月在河北医科大学第四医院收治的不可手术的中心型非小细胞肺癌患者44例,均经组织学或细胞学证实,采用SIB-CR技术制定放疗计划,PTV处方剂量5 040 c Gy/28次(180 c Gy/次),肿瘤局部处方剂量6 440 c Gy/28次(单次分割230 c Gy/次),1次/日,5次/周,全程放疗时间5.5周。观察不良反应及临床疗效。结果放疗结束疗效显示:总有效率为97.70%(43/44)。全组病例1、2、3、5年生存率分别为70.9%、44.8%、31.0%、18.6%。1、2、3、5年局部控制率分别为93.8%、63.9%、58.1%、58.1%。急性放射性肺炎和放射性食管炎的发生率分别为29.6%和25%。骨髓抑制发生率为43.2%(19/44)。结论全程局部同步推量适形放射治疗不可手术的中心型非小细胞肺癌,临床有效率高,患者耐受性好。长期生存和晚期并发症有待于进一步观察。
